RSV is a contagious virus that can lead to hospitalization and other complications, especially in older adults. In the United States, an RSV vaccine (ABRYSVO®) has been approved for adults 60 years of age and older. However, more research is needed before it can be approved for use in other countries.
This clinical trial will help further evaluate the safety and immune response generated by the RSV vaccine in adults 60 years of age or older. The results of this clinical trial may support the vaccine’s approval outside of the United States.
If this clinical trial is a good fit for you and you agree to participate, you will receive one injection of the RSV vaccine (ABRYSVO®). This clinical trial does not include a placebo (an injection with no active ingredient).
Qualified Participants Must:
- Be at least 60 years of age
-
Are generally healthy with no major changes in recent medical history
-
Have not received a previous RSV vaccine or plan to receive one (other than the study vaccine) during the study
-
Do not have a history of severe side effects from or allergic reactions to any vaccine
There are other requirements that our team will discuss with you to see if you qualify.
Qualified Participants May:
- Receive compensation for time and travel
- See a study doctor at no cost
- Receive access to study medications
RSV Vaccine Research Study
Compensation
May be available for time and travel for those who qualify. No cost to participate. Health insurance not required.
Eligible Ages
Open to people aged 60+
Apply to Participate
Please fill out the form to see if you qualify to participate.